[New strategies for BMT].
Using various autoimmune-prone mice, we have previously shown that conventional allo BMT can be used to treat a range of autoimmune diseases. These findings have recently been confirmed even in humans. However, in humans, the success rate of BMT across major histocompatibility complex(MHC) barriers is lowered by graft-versus-host disease(GvHD), graft rejection, and incomplete T-cell recovery. We have just established a new BMT method in which bone marrow cells(BMCs) are directly injected into the intra-bone marrow(IBM-BMT). We here show that 'IBM-BMT' is the best strategy for allo BMT and also organ allografts to induce persistent tolerance.
Ikehara
Susumu
S
First Department of Pathology, Transplantation Center, Regeneration Research Center for Intractable Diseases, Kansai Medical University.
D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000379:methods / Q000401:mortality / Q000473:pathology; D006801:Humans; D008181:Lupus Nephritis / Q000628:therapy; D051379:Mice; D014019:Tissue Donors